Navigation Links
Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study

atements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details and a discussion of risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's first quarter 2007 10-Q.

Media Contacts:
Mary-Fran Faraji
908)-247-6959 - mobile
Catherine Cantone
(908) 298-3944
(908) 327-3013 mobile

Investor Contact:
Alex Kelly
(908) 298-7436


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
2. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
3. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
6. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Alzheimers Drug Shows Promise in Fighting Cancer
11. Data on Telavancin and Micafungin Hold Promise of New Therapeutic Options in Fight Against Serious Infectious Disease

Post Your Comments:
(Date:11/25/2009)... 25 According to Millennium Resear...chnology market intelligence, the nearly $3 billio...nue to see rapid growth over the next five years d...kets for Trauma Devices 2010 report finds that ...xt five years, with competitors introducing specia...
(Date:11/25/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Intranasal Drug Delivery - US Market ...m/p0164267/Intranasal-Drug-Delivery---US-Market-Tr...delivery market is witnessing an expansion of ther...onal local therapeutic drugs to the delivery of sy...
(Date:11/24/2009)...v. 24 /PRNewswire-Asia/ -- Chindex International, ...endent American provider of Western,healthcare pro...na, today,announced that the Company will attend t...re Conference, to be held December 1 - 2, 2009, at...is currently scheduled to present at 11:30 am ET o...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Horizon Therapeutics HZT 501 Significantly Reduces Incidence of NSAID Induced Upper Gastrointestinal Ulcers in Patients With Mild to Moderate Pain 4506 1Horizon Therapeutics HZT 501 Significantly Reduces Incidence of NSAID Induced Upper Gastrointestinal Ulcers in Patients With Mild to Moderate Pain 4506 2Horizon Therapeutics HZT 501 Significantly Reduces Incidence of NSAID Induced Upper Gastrointestinal Ulcers in Patients With Mild to Moderate Pain 4506 3Horizon Therapeutics HZT 501 Significantly Reduces Incidence of NSAID Induced Upper Gastrointestinal Ulcers in Patients With Mild to Moderate Pain 4506 4Horizon Therapeutics HZT 501 Significantly Reduces Incidence of NSAID Induced Upper Gastrointestinal Ulcers in Patients With Mild to Moderate Pain 4506 5MHPA Leading Association Representing Medicaid Health Plans Issues Statement on Proposed California SCHIP Elimination 47534 1MHPA Leading Association Representing Medicaid Health Plans Issues Statement on Proposed California SCHIP Elimination 47534 2IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 1IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 2IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 3IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 4IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 5
...MAN, Mont., Sept. 18 LigoCyte Pharmaceuticals,Inc...ogen Idec (Nasdaq:,BIIB) to develop therapies targ...ory diseases including potential respiratory, gast...the unique alphaE-beta7 integrin that,has been imp... lymphocytes,that mediate inflammatory diseases af...
...ication for AML Remission Maintenance Therapy ... EMEA, TARRYTOWN, N.Y., Sept. 18 EpiCept Corpora...reported that the assessment,of its European Union...or,its lead oncology product Ceplene(TM) is advanc...ble following a meeting yesterday. Ceplene,(histam...
Other Medicine Technology:EpiCept Reports Regulatory Progress on Ceplene(TM) 2EpiCept Reports Regulatory Progress on Ceplene(TM) 3EpiCept Reports Regulatory Progress on Ceplene(TM) 4EpiCept Reports Regulatory Progress on Ceplene(TM) 5
(Date:11/27/2009)... , BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCal...pany"), a supplier of precision technology product...an annual meeting of the Company,s shareholders ha...time and location of the meeting will be announced...any received a requisition notice from Stephen Ber...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCall/ ...nced that Blair Lambert, CFO/COO, will present at ...e held at the May Fair Hotel in London, England, o...,, To listen to a live broadcast of The Gymbore...ease log on to www.gymboree.com, click on "Our Com...
(Date:11/27/2009)... XenaCare Holdings has announced...ritis Foundation, one of the largest nonprofit org...lic health education. , D...are Holdings, Inc. (OTCBB: XCHO), a company specia... consumer healthcare products, has announced today...
(Date:11/27/2009)... Voyant Health™ announced ...) has licensed its TraumaCad Enterprise orthopedic...flow solution. , (PRWEB) ...d today that Spectrum Health (Grand Rapids, Michig...ic templating solution and its TraumaCad Extend wo...
(Date:11/26/2009)..., NEW YORK, Nov. 27 With cold a...er to employ good practices to control the spread ... be proactive not only to keep ourselves healthy, ...said Eileen Finerty, RN, MS, CIC (certified in inf...ntrol and occupational health at Hospital for Spec...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
... replace the tissue it sloughs off is controlled b...ical School published// in the May 4 issue of Cell... regeneration process not only for skin, but for m...a close relative to the well-known tumor-suppressi...
... in the journal Proceedings of the National Academ...dus bacteria produce// an antibiotic which inhibit...ms use to defend themselves from attack. Alt...gle gene in an animal or human host have been iden...
... for treatment of a rare genetic condition that ca...rage life expectancy// of 13 years. Scientis...ysterious illnesses found the infants had mutation...more bad copies of the gene's primary protein, lam...
...Coalition on Tuesday launched a campaign to encour...apolis Star reports//. The obesity rate for U.S. H...2001. Hispanics residents are more likely to be ob...Diet Pyramid" that encourages Hispanics to eat tra...
...ay just feel the heart in their mouth when they re... risk of suffering a heart attack// have finally b...ublished in the Journal Science, has shown that on...king healthy lifestyle choices that may help cut d...
...stitute is seeking to raise glaucoma awareness amo... the disease than others, the Casa Grande Valley D... 60, blacks over age 40 and people with a family h... The rate increases to 8% among those in the...
Other Medicine News:Health News:Master Regulatory Gene of Epithelial Stem Cells Identified 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2Health News:New Clues for Treatment of Disease That Causes Accelerated Aging 2Health News:New Clues for Treatment of Disease That Causes Accelerated Aging 3Health News:The DNA That Spells Double Risk of Heart Attack 2
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...Macula Complete includes the nutrients used in the...plement Trial (LAST), which suggested no AMD disea...year period. Macula Complete also contains efficac...ed studies to support the mitochondria, as well as...
...Bausch & Lomb PreserVision® Soft Gel Lutein pa...ausch & Lomb PreserVision® AREDS formula, with...Glo Lutein., Lutein is a carotenoid found in dark... highly concentrated in the macula, the part of th...
Medicine Products: